|
Summary of metabolic markers at baseline and on the last day of combination therapy. |
|||||
| T/HCTZ |
V/HCTZ |
Difference* (T/HCTZ – V/HCTZ) |
|||
|
|
|||||
| Endpoint, mean ± SD |
Baseline |
Last day |
Baseline |
Last day |
p value |
|
|
|||||
| Serum triglyceride (mg/dL) |
201.7 ± 247 |
211.8 ± 172 |
196.3 ± 151 |
210.5 ± 177 |
0.91 |
| LDL-C (mg/dL) |
165.6 ± 35.4 |
169.8 ± 38.1 |
162.8 ± 33.9 |
165.3 ± 36.0 |
0.17 |
| HDL-C (mg/dL) |
37.1 ± 6.5 |
36.6 ± 6.3 |
37.6 ± 7.2 |
37.1 ± 7.0 |
0.64 |
| Total cholesterol (mg/dL) |
195.7 ± 23.3 |
198.5 ± 21.7 |
194.5 ± 19.8 |
196.3 ± 20.9 |
0.20 |
| Potassium (mEq/L) |
4.4 ± 0.4 |
4.5 ± 0.4 |
4.4 ± 0.4 |
4.4 ± 0.4 |
0.03 |
| Glucose (mg/dL) |
128.8 ± 44.1 |
138.8 ± 53.1 |
134.1 ± 49.2 |
140.4 ± 55.2 |
0.58 |
| HbA1c (%) |
6.5 ± 0.3 |
6.6 ± 0.3 |
6.6 ± 0.3 |
6.7 ± 0.4 |
0.93 |
| Albumin:creatinine ratio |
97.6 ± 330 |
65.1 ± 266 |
66.7 ± 239 |
45.1 ± 177 |
0.97 |
|
T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ: valsartan 160 mg plus HCTZ 12.5 mg; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycolated haemoglobin. *Analysis of change from baseline | |||||
Sharma et al. Cardiovascular Diabetology 2007 6:28 doi:10.1186/1475-2840-6-28 |
|||||